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Background: Peritoneal implantation metastasis of gastric cancer is the major reason for cancer recurrence after
radical operations. As a new chemotherapeutic agent, raltitrexed has been widely used in intravenous
chemotherapy for many kinds of cancers. However, no study has reported the efficacy and safety of raltitrexed in
intraperitoneal chemotherapy. This study aimed to explore the safety of intraperitoneal chemotherapy with
raltitrexed during gastric cancer operation compared to normal saline (NS) rinsing of the abdominal cavity.
Methods: In this prospective study, 91 gastric cancer patients undergoing surgery and reconstruction were
consecutively enrolled and randomly assigned into two groups. Raltitrexed in NS (500 ml) was injected into the
abdominopelvic cavity for the patients in the RT group (n = 48), while for the patients in the group NS (n = 43), only
NS (500 ml) was injected. The postoperative complications, gas passage time, and adverse effects, according to
NCI-CTCAE v3.0, were compared between the two groups.
Results: There were no significant differences in age, sex, cancer pathological type, clinical stage or operation
method between the two groups (all P >0.05). No significant difference was observed in adverse effects and
postoperative complications between the two groups (all P >0.05). No significant change was found in the levels of
red blood cells, white blood cells, platelets, lactate dehydrogenase, blood urea nitrogen, and alanine
aminotransferase before and after the operation for both groups (all P >0.05). All adverse events were mild or
moderate by NCI-CTCAE v3.0 (National Cancer Institute common terminology criteria for adverse events) grade.
Conclusions: The findings of the present study demonstrate that intraperitoneal chemotherapy with raltitrexed
after gastric cancer operation is safe and could be used for patients.
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Gastric cancer is one of the most common malignancies
in the world, and radical operations have been accepted
as the best choice for treating gastric cancer [1]. The de-
velopment of surgical techniques and equipment in the
past two decades has also improved the treatment of
gastric cancer, which has in turn improved the survival
rate and quality of life of the patients. Gastric cancer
surgery these days is performed based on cytological evi-
dence rather than the presence of lumps alone. Further
surgery ensures that there is no iatrogenic planting of
the tumor and provides radical treatment in cytological
terms. Based on cytological features, gastric cancer* Correspondence: zhaopingmedsci@163.com
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unless otherwise stated.operation outcome will include either advanced gastric
cancer with residual cancer (including residual cancer
seen by the naked eye and small cancerous lesions or
single cancer cells that cannot be observed by the naked
eye) or early gastric cancer without residual cancer, re-
gardless of the pre- or postoperative stages of the can-
cers [2-5]. However, the examination methods employed
in the present study restricted us from discriminating
micrometastasis from no metastasis.
Studies have reported that more than 70% of Chinese
patients are diagnosed with stage III or IV gastric cancer
at diagnosis and cannot be treated with radical surgery.
Therefore, a high proportion of patients have to be
treated with palliative surgery. In addition, radical oper-
ation cannot completely cure all patients. Surgical treat-
ment can only remove the tumors and adjacent lymphhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fied; however, cancer cells or cell clones that are spread
into other organs by invasion, hematogenous dissemin-
ation, or through the lymphatic system cannot be treated
with operations. Therefore, even radical operation can-
not prevent the recurrence or distant metastasis of the
cancers. The limited cancer cells that have entered the
lymph nodes could either proliferate to a large meta-
static tumor or be eliminated by the immune system; in
addition, several cells could also enter the G0 phase and
proliferate into a large metastatic tumor under appropri-
ate conditions [3-6].
Micrometastasis does not necessarily mean a poor out-
come but the free cancer cells in the abdominal cavity of
the patients are ‘time bombs’ that have the capacity to
proliferate and induce the recurrence and peritoneal im-
plantation metastasis [2]. Thus it is very important to
prevent the micrometastasis. One of the first steps in
this direction is to increase the detection rate. However,
the sensitivity and specificity of different methods vary
substantially with the peritoneal metastases. Metastases
that can be observed with the naked eye are easy to de-
tect, while micrometastasis means the cancer cells are
generally in the blood circulation, lymphatic vessels,
bone marrows, or other organs, and the sizes of cell
clones are <2 mm or have even not been formed, and
cannot be effectively detected by conventional examin-
ation including imaging or pathological examinations
[2]. Furthermore, no obvious clinical symptoms can sug-
gest micrometastasis. All these facts greatly limit our
knowledge about metastatic gastric cancers. Fortunately,
with the advance of biochemical technologies and new
tumor biomarkers, the methods of detecting microme-
tastasis have also greatly improved. These have also
brought forth more kinds of detection methods, for
example, the traditionally used serial sectioning method
was replaced by immunohistochemistry in the late
1980s, and application of polymerase chain reaction
(PCR) has further increased the detection rates [3,6-10].
Free cancer cells in the patient’s abdominal cavity are
mainly from cancer tissues, and when cancer cells invade
the gastric serosa they can also drop into the abdominal
cavity due to the reduced adhesive force among the can-
cer cells; in addition, free cancer cells could also come
from micrometastasis in the lymphatic system due to
the resection of lymphatic vessels during surgery. These
cancer cells that are free in the peritoneum could induce
the recurrence or metastasis of gastric tumors [6,11]. In
the past two decades, free cancer cells in the peritoneal
lavage of gastric cancer patients have been used as an
important specimen by Japanese researchers. In a study
performed by Kostic et al. [4], peritoneal lavage of 100
patients with gastric cancer was used for the diagnosis
of the disease, and the detection rate was 24%, which isconsistent with the results reported by Chuwa et al.
(35.4%) [5] and Kodera et al. (24 to 39%, mainly 14 to
21%) [12]. However, this method also involves relatively
high rates of false negatives [13]. In recent years, the de-
velopment of RT-PCR and the advancement of different
tumor biomarkers, especially keratin, have greatly im-
proved the sensitivity and detection rate of the detection
methods [14,15]. Intraperitoneal administration of che-
motherapeutic agents to eliminate the cancer cells can
prevent tumor recurrence [8-11]. Intraperitoneal chemo-
therapy allows the direct reaction between the drugs and
the surface of the peritoneum and the organs in the ab-
dominal cavity, thus the cancer cells that have dropped
from cancer tissues or other small cancer cell clones can
be effectively killed, which in turn can prevent the local
recurrence of gastric cancer. Many studies have investi-
gated the methods and drugs used in preventing periton-
eum metastasis. Several agents including cisplatin, 5-FU,
hydroxycamptothecin, and slow-release Sinofuan have
been used for intraperitoneal chemotherapy [8-11]. But
more recently, perioperative intravenous chemotherapy
has more often been the preferred treatment [16].
Occasional studies have included raltitrexed, a chemo-
therapeutic drug with a long half-life, in the treatment
combination used for intravenous chemotherapy of gas-
tric cancer [17,18]. In those cases, the intravenous dos-
ing regimens range from 1 mg/m2 to 3 mg/ml2 and were
well tolerated, although one study suggested that there
was no substantial antitumor activity using raltitrexed
for gastric cancer intravenously [18]. Pharmacokinetic
analysis of raltitrexed in cancer therapy has shown that
dose limiting toxicity occurred at 4.8 and 7.5 mg/m2/day
and that the maximum tolerated dose was 12 to 16 mg/
m2/day [19]. Animal models of intraperitoneal adminis-
tration of raltitrexed suggest that it is nontoxic at 1 and
2 mg doses in pigs and up to 8 mg/m2 in rats [20,21].
Based on this information and our experience, ralti-
trexed has been used in intraperitoneal chemotherapy, at
a dose of 4 mg, for gastric cancer patients after radical
operation between January and July 2013 in our hospital.
This study investigated the safety of raltitrexed for use in
a preliminary report on this chemotherapy method.
Methods
Patients
Ninety-one patients with gastric cancer who had been
treated in the department of Gastric Surgery, Cancer
Hospital of Sichuan Province, between January 2013 and
July 2013 were included in this study. Sixty-two of these
patients were males, and 29 were females. The ages of
the patients ranged from 37 to 72 years.
The inclusion criteria were patients with 1) invasion of
the adjacent tissues or extraserosal areas were identified
during the gastric cancer operation; 2) patients with
Table 1 Baseline clinical characteristics of the 91 patients
Parameter Raltitrexed (RT)
group n = 48
Normal saline
(NS) group n = 43
P value
Age (years) 56.4 ± 12.8 54.3 ± 11.2 >0.05









Mucoid carcinoma 11 10
Signet-ring cell 8 9








Distal gastrectomy 17 15
Proximal gastrectomy 6 7
Total gastrectomy 25 21
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who were treated with a palliative or radical operation.
The exclusion criteria were patients with diabetes,
more than 75 years of age, who had not received chemo-
therapy before the operation, or who were unsuitable for
chemotherapy.
This study was approved by the ethics committee of
the Cancer Hospital of Sichuan Province. All included
patients provided informed consent.
Study design
The patients were randomly assigned into two groups by
a computer-generated random number table, namely the
raltitrexed (RT) group (48 patients) and the normal sa-
line (NS) group (43 patients).
Conventional open operation was performed for all
the patients. No-tumor procedures (including applying
incise drape to the incisions, exploring the no-tumor re-
gions prior to exploring the tumor regions, minimizing
touching of the tumor, avoiding applying pressure to the
tumor and ligating the vessels around the tumors first)
were performed strictly to avoid iatrogenic planting and
spread. After the gastric cancer had been removed and
reconstruction had been performed, 2,000 to 2,500 ml of
distilled water was used to rinse the abdominal cavity
before it was closed. Then 4 mg of raltitrexed in 500 ml
of normal saline (NS) was injected into the abdominal
cavity for the patients in the RT group, while no chemo-
therapeutic agent but only 500 ml of NS was injected for
the patients in the NS group. The injection solutions
were prepared prior to the surgery and were adminis-
tered according to the randomization by the surgeon
who was blinded to the study groupings. Raltitrexed dos-
age was administered according to the manufacturer’s
instructions that 3 mg/square meter be supplied as 500
ml 0.9% NS injection. The drainage tube was clamped
for 2 hours after the operation to prevent the chemo-
therapy drugs from flowing from the peritoneal cavity.
Safety evaluation
The effects of the treatments on the recovery, abdominal
cavity and functions of other organs were evaluated
according to the common toxicity criteria issued by the
National Cancer Institute [2]. Complications including
fever for more than 3 days, pulmonary infection, and
anastomotic leakage were recorded. In addition, other
parameters including gas passage time, drug allergy,
abdominal drainage volume, peritoneal irritation signs
(including abdominal pain and pressing pain), gastro-
intestinal toxic reaction (including vomit, diarrhea, and
hemorrhage), hematologic toxic reaction (including white
blood cell count, red blood cell count, and platelet count
before and 7 days after the operation), renal toxicity
(including elevation of blood urea nitrogen (BUN) andcreatinine), and hepatotoxicity (including elevation of en-
zymes like alanine aminotransferase) were also measured.
Adverse events were reported according to the National
Cancer Institute common terminology criteria for adverse
events (NCI-CTCAE v3.0; http://ctep.cancer.gov).
Statistical analysis
SPSS 16.0 software (SPSS Inc., Chicago, Illinois, USA)
was used for the statistical analysis. Quantitative data
were described by means and standard deviations, and
analyzed by Student’s unpaired t-test between groups,
whereas qualitative data were described by proportions




The clinical characteristics of the patients in the RT and
NS groups are listed in Table 1. No significant difference
was found in age, sex, pathological type, clinical stages, and
operation method between the two groups (P >0.05). Thus,
the background data for all patients was relatively similar.
Incidence of postoperative complications
Incidences of postoperative complications in the RT and
NS groups are listed in Table 2. No significant difference
Table 2 Postoperative complications in the patients in
the two groups
Parameter Raltitrexed group
(RT) n = 48
Normal saline
group (NS) n = 43
P value
Pulmonary infection 2 2 >0.05
Incision infection 2 3 >0.05
Anastomotic leakage 0 0
Gas passage time
(hours)
3.43 ± 0.92 3.54 ± 0.86 >0.05
Abdominal drainage
volume (ml)




Table 3 Toxic and adverse effects in the patients in the
two study groups
Parameter Raltitrexed
group (RT) n = 48
Normal saline




Preoperative 3.68 ± 0.22 3.76 ± 0.14 >0.05
Postoperative 3.49 ± 0.21 3.56 ± 0.24 >0.05
WBC (109/L)
Preoperative 4.73 ± 0.46 4.45 ± 0.54 >0.05
Postoperative 6.29 ± 0.63 6.70 ± 0.52 >0.05
Platelet count (109/L)
Preoperative 183.09 ± 27.19 178.22 ± 28.24 >0.05
Postoperative 196.15 ± 25.28 192.36 ± 23.75 >0.05
Renal toxicity BUN
(mmol/L)
Preoperative 4.38 ± 0.72 4.46 ± 0.75 >0.05
Postoperative 4.87 ± 1.04 4.68 ± 0.84 >0.05
Renal toxicity
Creatinine (μmol/L)
Preoperative 76.24 ± 7.67 73.46 ± 6.95 >0.05
Postoperative 78.37 ± 7.44 74.68 ± 7.14 >0.05
Hepatotoxicity (U/L)
ALT
Preoperative 21.36 ± 2.78 19.92 ± 2.84 >0.05
Postoperative 24.35 ± 3.02 22.01 ± 2.65 >0.05
LDH (mmol/L)
Preoperative 186.46 ± 27.19 192.34 ± 32.45 >0.05
Postoperative 191.24 ± 26.76 190.56 ± 30.12 >0.05
Note: One case was found with low granulocyte count in each of the two
groups, and another case in group A was found with low hemoglobin level.
ALT, alanine aminotransferase; BUN, blood urea nitrogen; LDH, lactate
dehydrogenase; RBC, red blood cell; WBC, white blood cell.
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incision infection, gas passage time, abdominal drainage
volume, and peritoneal irritation signs between the two
groups (P >0.05). No anastomotic leakage was found in
either of the two groups.
Toxic effects in the two groups
Toxic effects in the RTand NS groups are listed in Table 3.
When assessing hematologic toxicity, it was found that
there were no significant differences in parameters like red
blood cell (RBC), white blood cell (WBC), and platelet
counts between the two groups, either before or after the
operation (P >0.05). One patient in group A had the low-
est granulocyte count of 1.2 × 109/L and platelet count of
3 × 109/L; another patient in the group B had a granulo-
cyte count of 2.2 × 109/L and platelet count of 6 × 109/L.
Drugs were used to stimulate the proliferation of white
blood cells for these two patients, and the granulocyte
count and hemoglobin level recovered to normal levels at
14-day postoperation. No significant difference in BUN,
alanine aminotransferase (ALT), lactate dehydrogenase
(LDH), and gastrointestinal toxic reactions between the
two groups, either before or after chemotherapy (P >0.05).
No congestive heart failure, interstitial pneumonia (proven
by X-ray), central coma, or peripheral numbness was
found in either group. However, one case of drug rash was
found in each of the two groups.
When toxic and adverse events were classified accord-
ing to the NCI-CTCAE v3.0, there were no significant
differences between the groups (Table 4). The most
common were eight cases of abdominal ache in the RT
group and nine cases in the NS group; six cases of hep-
atotoxicity in the RT group and five cases in the NS
group; and five cases of infection in the RT group and
six cases in the NS group. All of the reported events
were grade I or II and therefore were mild or moderate.
Discussion
This study evaluated the safety of intraperitoneal chemo-
therapy with raltitrexed in gastric cancer patients,comparing the chemotherapy with a placebo in the form
of normal saline. Results showed that this chemotherapy
is a safe method of treating these patients.
Lymphatic metastasis and intraperitoneal dissemin-
ation of cancer cells are two main reasons for gastric
cancer recurrence after radical resection. Peritoneal im-
plantation metastasis could be caused by the direct
spread of the gastric cancer cells or breakage of lymph-
atic metastasis. With the advance of related technolo-
gies, many methods for measuring micrometastatic
cancer cells can also be used for the determination of
the clinical stages, pathological types, and other features
involved in the peritoneum metastasis of gastric cancer,
and these have demonstrated that most patients have
peritoneal metastasis of gastric cancer [2,5,12].
Studies have reported that intraoperative rinse and
perioperative intraperitoneal chemotherapy can effect-
ively eliminate the presence of free cancer cells [22] and
Table 4 Toxic and adverse effects in patients in the two study groups (According to NCI-CTCAE v3.0)
Parameter Raltitrexed group (RT) n = 48 Normal saline group (NS) n = 43
I II III IV V I II III IV V
WBC 3 2 1 0 0 3 2 0 0 0
Platelet count 2 2 0 0 0 3 2 0 0 0
Bleeding 0 0 0 0 0 0 0 0 0 0
Renal toxicity 3 0 0 0 0 3 0 0 0 0
Hepatotoxicity 5 1 0 0 0 4 1 0 0 0
Fever (postoperation >7 days) 0 0 0 0 0 0 0 0 0 0
Infection 5 0 0 0 0 6 0 0 0 0
Diarrhea 2 0 0 0 0 3 0 0 0 0
Vomiting 3 2 0 0 0 3 1 0 0 0
Constipation 4 1 0 0 0 5 1 0 0 0
Cardiac function 0 0 0 0 0 0 0 0 0 0
Pneumonia (X-ray) 2 0 0 0 0 2 0 0 0 0
Peripheral numbness 0 0 0 0 0 0 0 0 0 0
Allergic reaction 2 0 0 0 0 3 0 0 0 0
Abdominal ache (postoperation >7 days) 7 1 0 0 0 8 1 0 0 0
NCI-CTCAE, National Cancer Institute common terminology criteria for adverse events; WBC, white blood cell.
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during operation has been regarded as an effective
method in treating gastric cancer. Studies have demon-
strated that intraperitoneal injection could increase the
efficacy of medication to ten- or even 1000-fold that of
intravenous injection [23] and that blood concentrations
of drugs are related to the ability to eliminate cancer
cells. A previous study has estimated that chemothera-
peutic drugs could eliminate ten times the number of
cancer cells when drug concentrations at the tumor/
target site are increased at one time point [24].
The peritoneal-plasma barrier can decrease the clear-
ance of chemotherapeutic drugs and thus increase the
drug treatment time, which could effectively increase the
damage to the cancer cells caused directly by the drugs.
In addition, chemotherapeutic drugs could be absorbed
by the peritoneum and enter the circulation system
through the portal system and the retroperitoneal lymph-
atic system, which is consistent with the metastatic path-
way of gastric cancer, and thus could increase the
possibility of eliminating micrometastatic lesions in the
lymphatic system and liver, and in turn, reduce the risk of
hepatic metastases.
Many drugs including Melphalan, 5-FU, Mitoxantrone,
Adriamycin, and Topotecan have been used in intraperi-
toneal chemotherapy; however, some other drugs includ-
ing cisplatin, Paclitaxel, and Carboplatin are more
commonly used in clinical practices for the treatment of
gastric cancers, especially cisplatin, which has the most
comprehensive clinical data. Studies have reported that
the concentration of cisplatin on the surface of thetumors is ten- to 20-fold greater when administered in-
traperitoneally versus intravenously, whereas the drug
concentration in the peripheral blood is significantly
lower than when administered intravenously. The severe
adverse effects of cisplatin have also been a challenge for
clinicians. Long-term use of cisplatin can induce resist-
ance in most patients, which could increase the recur-
rence rate of the cancer. The relatively low molecular
weight of cisplatin allows rapid absorption of this drug
into blood, which could increase the systematic adverse
effects. Recently, several studies have focused on investi-
gating embedding cisplatin in liposomes by fibrin sealant
or other sustained-release matrix materials to reduce
excretion of the drug. Currently, rinsing the abdominal
cavity with 5-FU or even distilled water is widely ap-
plied as a part of radical resection of gastric cancer. As
a first-line chemotherapy drug for gastrointestinal can-
cer, 5-FU has also been chosen as a chemotherapy drug
for intraperitoneal chemotherapy [25,26]. As a sensitive
anti-metabolism drug, 5-FU needs to be metabolized to
activate metabolites after absorption and then eliminate
the cancer cells [1,27].
The clearance of drugs is dependent on two factors,
namely the characteristics of the drug and peritoneum.
Drugs with higher molecular weight generally have lower
fat-solubility, and are cleared from abdominal cavity
more slowly, which could increase the reaction time be-
tween the drug and tumor and allow the drugs to pene-
trate deep into the tumor tissues. The molecular weight
of raltitrexed is 458, which is much higher than that of
cisplatin and 5-FU; in addition, the half-life of raltitrexed
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react with cancer cells for a long time without using a
slow-release drug matrix. However, no previous study
has investigated the safety and efficacy of intraperitoneal
chemotherapy with raltitrexed.
Raltitrexed is a specific inhibitor of water soluble thy-
midylic acid synthase, which can be actively absorbed by
cells through cell membrane carriers in its reduced form
of methotrexate and can be metabolized into different
polyglutamic acids within the cells that react with cancer
cells for a long time with higher efficacies than raltitrexed.
The long half-life of raltitrexed makes it a promising can-
didate of intraperitoneal chemotherapeutic drug.
Previously, raltitrexed has been used as a postoperative
chemotherapeutic drug for colorectal, gastric, and breast
cancers in combination with oxaliplatin instead of 5-FU
[28,29].
This study has some limitations. The relatively small
sample size of the present study limited the statistical
power of the study; thus these findings should be inter-
preted with caution, and further studies with larger sam-
ple sizes are warranted to validate our findings. This
study is just a preliminary study on the safety of the use
of raltitrexed; the effectiveness of this method of chemo-
therapy needs to be fully evaluated in longer term study.
In addition, we used the recommended dose of ralti-
trexed for injection; further studies are needed to inves-
tigate the pharmacokinetics and pharmacodynamics of
raltitrexed while using it as an intraperitoneal chemo-
therapeutic drug.
To conclude, we believe that raltitrexed could be bet-
ter suited for intraperitoneal chemotherapy than 5-FU
given its unique characteristics. It showed no obvious
local irritation symptoms (including peritoneal inflam-
matory response, substantially increased drainage vol-
ume, or adhesive intestinal obstruction) when 2 mg of
raltitrexed was used, or when the dose was increased to
4 mg for further analysis.
Conclusions
The findings of the present study showed that there
were no significant differences in the postoperative gas
passage time, mean drainage volume (3 days after the
operation), and other complications (including incision
infection, pulmonary infection, anastomotic leakage,
fever for more than 3 days after the operation, postoper-
ative drainage volume, peritoneal irritation signs, and
postoperative diarrhea) between the two groups, suggest-
ing that intraperitoneal chemotherapy with raltitrexed
did not increase the risk of the operation. In addition,
no significant difference was found while comparing
hematologic toxicity, renal toxicity, hepatotoxicity, and
cardiac disease parameters before and at 7 day after the
operation, in each of the two groups. The toxic andadverse events were all graded as I or II according to
NCI-CTCAE v3.0 and therefore were mild or moderate.
Furthermore, no systematic drug reaction was found in
the patients who received raltitrexed, which could be
because only limited amounts of the drug could be
absorbed into the blood or lymphatic system, and thus
only a low dose of the drug could reach other organs;
therefore, the effects and side-effects of intraperitoneal
chemotherapeutic drugs are mainly focused within the
abdominal cavity, and induce only limited systematic ad-
verse effects. The findings of the present study demon-
strate that intraperitoneal chemotherapy with raltitrexed
shows good safety.
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